Technical Analysis for CYBN - Cybin Inc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 12.21% | |
Wide Bands | Range Expansion | 12.21% | |
Oversold Stochastic | Weakness | 12.21% | |
NR7 | Range Contraction | 10.14% | |
Narrow Range Bar | Range Contraction | 10.14% | |
Wide Bands | Range Expansion | 10.14% | |
Oversold Stochastic | Weakness | 10.14% | |
Wide Bands | Range Expansion | 8.13% | |
Oversold Stochastic | Weakness | 8.13% | |
NR7 | Range Contraction | 12.21% |
Alert | Time |
---|---|
Gap Down Closed | about 4 hours ago |
Rose Above Previous Day's High | about 4 hours ago |
Reversed from Down | about 4 hours ago |
Rose Above 10 DMA | about 4 hours ago |
Up 1 ATR | about 4 hours ago |
Get a Trading Sidekick!
- Earnings date: Unknown
Cybin Inc Description
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Entheogens Biopharmaceutical Ayahuasca Major Depressive Disorder Serotonin Receptor Agonists
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 37.24 |
52 Week Low | 9.5 |
Average Volume | 11,862 |
200-Day Moving Average | 17.301 |
50-Day Moving Average | 13.395 |
20-Day Moving Average | 11.723 |
10-Day Moving Average | 10.450 |
Average True Range | 0.844 |
RSI (14) | 26.47 |
ADX | 46.38 |
+DI | 5.419 |
-DI | 29.226 |
Chandelier Exit (Long, 3 ATRs) | 11.719 |
Chandelier Exit (Short, 3 ATRs) | 12.031 |
Upper Bollinger Bands | 14.474 |
Lower Bollinger Band | 8.972 |
Percent B (%b) | 0.2 |
BandWidth | 46.937 |
MACD Line | -0.984 |
MACD Signal Line | -0.893 |
MACD Histogram | -0.0912 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 10.640 | ||||
Resistance 3 (R3) | 10.640 | 10.450 | 10.545 | ||
Resistance 2 (R2) | 10.450 | 10.305 | 10.450 | 10.513 | |
Resistance 1 (R1) | 10.260 | 10.215 | 10.260 | 10.260 | 10.482 |
Pivot Point | 10.070 | 10.070 | 10.070 | 10.070 | 10.070 |
Support 1 (S1) | 9.880 | 9.925 | 9.880 | 9.880 | 9.658 |
Support 2 (S2) | 9.690 | 9.835 | 9.690 | 9.627 | |
Support 3 (S3) | 9.500 | 9.690 | 9.595 | ||
Support 4 (S4) | 9.500 |